Research Progress in New Dosage Forms of Anti-tumor Drugs for Pulmonary Administration
10.3969/j.issn.1008-049X.2018.03.036
- VernacularTitle:抗肿瘤药物肺部给药新剂型研究进展
- Author:
Chunqing LU
1
;
Yiping ZHENG
;
Ya'nan GAO
;
Jingling TANG
Author Information
1. 哈尔滨医科大学药学院 哈尔滨150086
- Keywords:
Lung cancer;
Pulmonary administration;
Anticancer drugs;
Liposomes;
Nanoparticles
- From:
China Pharmacist
2018;21(3):493-496
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the most common malignancies. Anti-tumor drugs with intravenous administration have systemic adverse effects as well as limited efficacy. Drugs can concentrate in lungs after pulmonary administration,which limits the distribution in the other organs and reduces the side effects of anti-tumor drugs. The paper focused on the recent progress in the studies on new dos-age forms of anti-tumor drugs for pulmonary administration for the therapy of lung cancer,so as to provide reference for the development of anti-tumor drugs for pulmonary administration.
